Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab
| Autor: | Xuehua Ke, Benjamin Ortiz, Qing Huang, Vincent J. Willey, Judith J. Stephenson, Jonathan Corren, Reynold A. Panettieri, Liya Wang, Debra A. Wertz, Abhishek Kavati |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Health plan
Adult Male medicine.medical_specialty Index date Exacerbation Adolescent Omalizumab 03 medical and health sciences Young Adult 0302 clinical medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Anti-Asthmatic Agents Child Asthma Aged Pharmacology business.industry Medical record Allergic asthma Middle Aged medicine.disease United States Hospitalization 030228 respiratory system Concomitant Emergency medicine Female business Emergency Service Hospital medicine.drug |
| Zdroj: | Clinical therapeutics. 40(7) |
| ISSN: | 1879-114X |
| Popis: | The objective of this study was to examine patient characteristics, treatment patterns, and exacerbations among patients with asthma newly treated with omalizumab.Data for this study were obtained from administrative claims and medical records. The index date was the date of the first claim for omalizumab. All patients had ≥12 months of continuous health plan eligibility before and after the index date. Demographic and clinical characteristics were obtained 12 months before the index date. Treatment patterns of asthma medications, including omalizumab, and asthma exacerbations were evaluated in the preindex and postindex periods.The study included 1564 patients. Asthma-related medication use decreased from the preindex to the postindex periods (oral corticosteroids, 83.3%-66.4%, P0.001; inhaled corticosteroids [ICSs], 33.1%-26.8%, P0.001; long-acting βIn this real-world analysis, patients newly initiating omalizumab therapy for allergic asthma used fewer concomitant asthma medications, while experiencing significant reductions in asthma exacerbations, especially hospitalization- and emergency department-specific exacerbations, from pre- to post-omalizumab treatment initiation periods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect